Stent Leaders Pull Out Of India Amidst Price Cap Storm; Opportunity For 'The Dragon'?
Executive Summary
The storm in India over price caps on stents has not shown any signs of abating, with foreign firms seeking to pull back certain key brands and the pricing regulator resolute about maintaining market equilibrium. The slugfest also appears to have opened up the Indian market for Chinese firms, among others.
You may also be interested in...
India's Device Price Cap Storm Rages On: New Stent Cap And Spotlight On Catheter Trade Margins
India’s medical device pricing storm looks unlikely to abate any time soon, with another round of price caps on stents being enforced. The spotlight is also shining on the sharp variances in trade margins for catheters in the country.
OUS Approvals Analysis: Small Companies Dominate International Approvals In April
April was a return to a more typical volume of medical device approvals outside the US after a particularly busy March. And the big names in medtech were mostly quiet in April's OUS approvals, according to Medtech Insight's Approval Tracker.
India Specifies Terms For Ceasing Supplies Of Essential Drugs
India's apex pricing authority has specified the modalities for firms wanting to stop supplies of certain essential drugs in the country. Industry, though, claims that the regulator may have exceeded its remit and underscores how a lopsided pricing policy approach can lead to potential shortages.